Navigation Links
Defending against chemical acts of terrorism
Date:4/20/2012

Researchers may have found a way to protect us against otherwise deadly chemical attacks, such as the subway sarin incident in Tokyo that left thirteen people dead and thousands more injured or with temporary vision problems. The method is based on a new and improved version of a detoxifying enzyme produced naturally by our livers, according to the report in the April 2012 issue of Chemistry & Biology, a Cell Press publication.

"The sarin attack in Tokyo in 1995 demonstrated that both the raw materials and know-how of producing deadly nerve agents are available to people outside government or military institutions," said Moshe Goldsmith of the Weizmann Institute of Science in Israel. "We hope that our work would provide a prophylactic drug that will effectively protect the medical, police, and other teams that will have to act in a contaminated area following such an attack and would also provide these teams with a drug that could be administered on-site to intoxicated individuals to greatly improve their chances of survival."

Today, protection against nerve agents relies primarily on physical barriers such as gas masks and protective suits that can easily be breached, Goldsmith explained. Following exposure, people are treated with drugs that help with the symptoms but don't eliminate the nerve agent.

Goldsmith and the study's senior author Dan Tawfik hope to change this, relying on the principles of evolution to produce a more efficient version of an enzyme that occurs naturally in all of us. Known as paraoxonase 1 (PON1), this enzyme was originally named for its ability to assist in the breakdown of the insecticide paraoxon. It is also involved in drug metabolism and detoxification.

PON1 normally does counteract G-type nerve agents, including sarin, tabun, soman, and cyclosarin, but not well enough. Tawfik's lab specializes in a technique called "directed enzyme evolution,"in which they artificially introduce mutations into the gene encoding a target enzyme, in this case PON1. The mutated versions of the gene are then put back into bacteria, which produce the enzymes for testing. The goal was to end up with enzymes capable of detoxifying G-type nerve agents before those nerve agents could reach their target and cause harm. Those that passed the initial test went on to further rounds of evolution and testing.

After four rounds of evolution, the researchers obtained PON1 variants that worked up to 340 times better than those produced previously. Overall, the researches reported that the PON1 variants showed 40- to 3,400-fold higher efficiency than the normal enzyme in metabolizing the three most toxic G-type nerve agents.

These new and improved PON1 enzymes have become promising candidates for use as preventive and postexposure treatments in the event of a terrorist attack.

"We hope that our enzymes would be able to act together with currently available drugs to improve survival rates following intoxication," Goldsmith said. More broadly, the findings show the power of laboratory evolution to completely reshape existing enzymes for a variety of uses.


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related biology technology :

1. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
2. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
3. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
4. MU researchers identify key plant immune response in fight against bacteria
5. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
6. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
7. Taksta™ (fusidic acid) Demonstrates Activity Against MRSA Isolated From Cystic Fibrosis Patients
8. SomaGenics sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus
9. Kelly Price Joins Los Angeles County Affiliate of Susan G. Komen for the Cure in the Fight Against Breast Cancer
10. World Hepatitis Alliance Warns that Stigma is a Major Threat to New Initiative Against Hepatitis Epidemic
11. Trudeau Institute announces a discovery in the fight against sepsis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... BC, Canada (PRWEB) , ... July 20, 2017 , ... ... today announced the winning recipients of the 2017 IAC Awards at the 22nd World ... awards, the committee also named four faculty to receive the Distinguished Fellowship Awards. , ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... on digital pathology and artificial intelligence Tuesday, July 25, during the Association of ... from Johns Hopkins Medicine. , Baras, Associate Director of Pathology Informatics, will ...
(Date:7/20/2017)... ... July 20, 2017 , ... Crucial Data Solutions (CDS) ... study participants truly unified. TrialKit, a native mobile app, empowers investigators and clinicians ... studies entirely on mobile devices. With TrialKit, clinical researchers can utilize Core Motion ...
(Date:7/18/2017)... Switzerland (PRWEB) , ... July 18, 2017 , ... ... R&D, today announced that Merck, a leading science and technology company, has implemented ... innovative therapeutics for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. , ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):